News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
505,328 Results
Type
Article (31342)
Company Profile (128)
Press Release (473858)
Multimedia
Podcasts (99)
Webinars (15)
Section
Business (159215)
Career Advice (1688)
Deals (25603)
Drug Delivery (95)
Drug Development (60735)
Employer Resources (115)
FDA (11324)
Job Trends (11175)
News (262541)
Policy (24061)
Tag
Academia (1685)
Academic (1)
Accelerated approval (6)
Adcomms (15)
Allergies (69)
Alliances (42152)
ALS (82)
Alzheimer's disease (1019)
Antibody-drug conjugate (ADC) (114)
Approvals (11355)
Artificial intelligence (249)
Autoimmune disease (21)
Automation (15)
Bankruptcy (240)
Best Places to Work (8575)
BIOSECURE Act (13)
Biosimilars (83)
Biotechnology (58)
Bladder cancer (70)
Brain cancer (24)
Breast cancer (260)
Cancer (2005)
Cardiovascular disease (163)
Career advice (1439)
Career pathing (27)
CAR-T (109)
CDC (21)
Cell therapy (352)
Cervical cancer (16)
Clinical research (50238)
Collaboration (828)
Compensation (282)
Complete response letters (18)
COVID-19 (1826)
CRISPR (50)
C-suite (235)
Cystic fibrosis (72)
Data (2165)
Decentralized trials (2)
Denatured (31)
Depression (36)
Diabetes (241)
Diagnostics (4140)
Digital health (12)
Diversity (4)
Diversity, equity & inclusion (34)
Drug discovery (108)
Drug pricing (113)
Drug shortages (27)
Duchenne muscular dystrophy (94)
Earnings (67782)
Editorial (41)
Employer branding (14)
Employer resources (103)
Events (77821)
Executive appointments (682)
FDA (12463)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (600)
Gene editing (97)
Generative AI (22)
Gene therapy (305)
GLP-1 (614)
Government (3015)
Grass and pollen (5)
Guidances (161)
Healthcare (12013)
Huntington's disease (18)
IgA nephropathy (27)
Immunology and inflammation (107)
Immuno-oncology (6)
Indications (31)
Infectious disease (1920)
Inflammatory bowel disease (120)
Inflation Reduction Act (11)
Influenza (36)
Intellectual property (93)
Interviews (293)
IPO (11516)
IRA (45)
Job creations (2992)
Job search strategy (1214)
Kidney cancer (10)
Labor market (34)
Layoffs (326)
Leadership (18)
Legal (6078)
Liver cancer (44)
Lung cancer (292)
Lymphoma (148)
Machine learning (6)
Management (38)
Manufacturing (315)
MASH (71)
Medical device (7496)
Medtech (7501)
Mergers & acquisitions (14611)
Metabolic disorders (616)
Multiple sclerosis (72)
NASH (17)
Neurodegenerative disease (75)
Neuropsychiatric disorders (20)
Neuroscience (1502)
NextGen: Class of 2025 (4269)
Non-profit (2947)
Now hiring (15)
Obesity (317)
Opinion (212)
Ovarian cancer (63)
Pain (98)
Pancreatic cancer (73)
Parkinson's disease (125)
Partnered (14)
Patents (218)
Patient recruitment (91)
Peanut (29)
People (43746)
Pharmaceutical (67)
Pharmacy benefit managers (18)
Phase I (14675)
Phase II (21647)
Phase III (17750)
Pipeline (1379)
Policy (162)
Postmarket research (2217)
Preclinical (6337)
Press Release (44)
Prostate cancer (117)
Psychedelics (21)
Radiopharmaceuticals (211)
Rare diseases (348)
Real estate (4286)
Recruiting (46)
Regulatory (16704)
Reports (31)
Research institute (1621)
Resumes & cover letters (249)
Rett syndrome (7)
RNA editing (6)
RSV (25)
Schizophrenia (70)
Series A (105)
Series B (58)
Service/supplier (6)
Sickle cell disease (57)
Special edition (15)
Spinal muscular atrophy (113)
Sponsored (23)
Startups (2500)
State (2)
Stomach cancer (10)
Supply chain (53)
Tariffs (54)
The Weekly (66)
Vaccines (521)
Venture capitalists (29)
Weight loss (195)
Women's health (28)
Worklife (13)
Date
Today (77)
Last 7 days (386)
Last 30 days (1934)
Last 365 days (23790)
2025 (11806)
2024 (25808)
2023 (28730)
2022 (37453)
2021 (39578)
2020 (38305)
2019 (32409)
2018 (24515)
2017 (24367)
2016 (23789)
2015 (27575)
2014 (23027)
2013 (20068)
2012 (20617)
2011 (20550)
2010 (19252)
Location
Africa (679)
Alabama (48)
Alaska (5)
Arizona (127)
Arkansas (9)
Asia (32072)
Australia (4853)
California (4968)
Canada (1692)
China (501)
Colorado (239)
Connecticut (236)
Delaware (134)
Europe (69871)
Florida (865)
Georgia (167)
Idaho (29)
Illinois (453)
India (24)
Indiana (289)
Iowa (6)
Japan (181)
Kansas (80)
Kentucky (22)
Louisiana (8)
Maine (27)
Maryland (711)
Massachusetts (3912)
Michigan (160)
Minnesota (264)
Mississippi (1)
Missouri (49)
Montana (15)
Nebraska (14)
Nevada (51)
New Hampshire (33)
New Jersey (1621)
New Mexico (15)
New York (1466)
North Carolina (855)
North Dakota (6)
Northern California (2156)
Ohio (142)
Oklahoma (12)
Oregon (25)
Pennsylvania (1165)
Puerto Rico (10)
Rhode Island (27)
South America (952)
South Carolina (21)
Southern California (1959)
Tennessee (98)
Texas (745)
United States (19331)
Utah (147)
Virginia (145)
Washington D.C. (60)
Washington State (420)
West Virginia (3)
Wisconsin (46)
505,328 Results for "gan and lee pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
March 11, 2025
·
4 min read
Pharm Country
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association’s 84th Scientific Sessions
Gan & Lee Pharmaceuticals announced the presentation of three abstracts featuring their investigational products at the American Diabetes Association’s 84th Scientific Sessions.
June 17, 2024
·
3 min read
Pharm Country
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association’s 84th Scientific Sessions
Gan & Lee Pharmaceuticals announced the results of the Phase 1b/2a clinical study of the Company’s independently developed glucagon-like peptide-1 receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins’ preclinical studies in poster presentations at the American Diabetes Association’s（ADA’s）84th Scientific Sessions.
June 22, 2024
·
7 min read
Press Releases
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
November 11, 2024
·
5 min read
Press Releases
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
December 18, 2024
·
4 min read
Press Releases
Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
October 15, 2024
·
8 min read
Press Releases
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
November 12, 2024
·
4 min read
Press Releases
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
September 16, 2024
·
6 min read
Press Releases
Gan & Lee Pharmaceuticals’ Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
July 22, 2024
·
4 min read
Drug Development
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
Gan & Lee Pharmaceuticals Co., Ltd. is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.
October 14, 2021
·
2 min read
1 of 50,533
Next
